Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

RadioMedix Announces Receiving FDA Approval of Its Generic Ga-68 PSMA-11 Radiodiagnostic for Prostate Cancer

June 12, 2026

[RadioMedix, Inc.] RadioMedix, Inc. announced that the US FDA has approved Ga 68 PSMA-11, a prostate-specific membrane antigen (PSMA)-targeted diagnostic radiopharmaceutical for positron emission tomography imaging in patients with prostate cancer.

CPRIT Invests Over $11 Million to Fuel UH Breakthroughs in Cancer Research

June 12, 2026

[University of Houston] With $250,000 in Cancer Prevention and Research Institute of Texas (CPRIT) funding, Dr. Qin Feng, associate professor of biology and biochemistry, is working to stop the progression of prostate cancer. Her research goal is to provide a new treatment option for prostate cancer patients, especially those resistant to current therapies.

MCCC2 Stabilizes LTBP1 via Suppressing SMURF1-Dependent Ubiquitination to Drive Bone Metastasis in Prostate Cancer

June 12, 2026

[Oncogene] Liquid chromatography-mass spectrometry identified LTBP1 as a direct interacting partner of methylcrotonyl-CoA carboxylase subunit 2 (MCCC2). Functional studies demonstrated that MCCC2 promotes prostate cancer cell migration, invasion in vitro, and bone metastasis in vivo.

The CDK4/6 Inhibitor Dalpiciclib Augments the Antitumor Efficacy of Enzalutamide in Preclinical Models of Castration-Resistant Prostate Cancer through Inhibition of MCM4-Mediated DNA Replication

June 12, 2026

[Cell Death & Disease] Researchers conducted pharmacological profiling, genetic dependency analysis, RNA sequencing, and functional validation across various in vitro and in vivo preclinical CRPC models.

USP2 Is an Androgen-Repressed Survival Factor That Stabilises Oncoproteins to Facilitate Therapy Resistance in Prostate Cancer

June 12, 2026

[Cell Death & Disease] In prostate cancer, the development of resistance to androgen receptor-targeted therapies and chemotherapies is associated with the emergence of new phenotypic states with altered molecular features. Scientists identified ubiquitin-specific peptidase 2 (USP2) as a mediator of this phenomenon.

Epigenetic Modulation of Prostate Cancer Disparities in Men with African Ancestry

June 12, 2026

[Nature Reviews Urology] Drawing on multi-ancestral comparative analyses, with emphasis on cohorts from sub-Saharan Africa, the authors speculate that germline and somatic variation converge in epigenetic machinery genes to drive tumor evolution.

Co-Targeting EGFR and SUCLG2 Disrupts a Nuclear Transcriptional Program Driving Neuroendocrine Differentiation and TKI Resistance in Castration-Resistant Prostate Cancer

June 12, 2026

[Cell Communication and Signaling] Through integrated molecular and functional analyses, researchers identified the mitochondrial succinyl-CoA ligase subunit SUCLG2 as a critical driver of neuroendocrine differentiation and EGFR-tyrosine kinase inhibitor resistance.

Gut Microbial Metabolism of Flutamide Attenuates Its Therapeutic Efficacy against Prostate Cancer

June 12, 2026

[Gut Microbes] Scientists explored the role of gut microbiota in modulating Flutamide metabolism and antitumor efficacy. They investigated whether intestinal bacteria, particularly Escherichia coli, metabolizesFlutamide into inactive derivatives, and further assessed how microbial metabolites of Flutamide influence its efficacy.

Epigenetic and Oncogenic Inhibitors Converge to Drive a Metabolic Catastrophe in Castration-Resistant Prostate Cancer

June 12, 2026

[Journal of Clinical Investigation] Researchers showed that EZH2 inhibitors synergize with PI3K, AKT, or mTORC1 inhibitors to kill CRPC in vitro and promote tumor regression in vivo.

Targeting the ELF1/EGFR/ERK Positive Feedback Loop Overcomes Resistance to Androgen Receptor Inhibition in AR-Vs Positive Prostate Cancer

June 12, 2026

[Neoplasia] Investigators reported that prolonged exposure of prostate cancer cells expressing both AR splice variants (AR-Vs) and AR-Vs to enzalutamide induces extensive reprogramming of their transcriptomic and proteomic profiles.

CDO1 Is a New Biomarker to Discriminate Aggressive Forms of Prostate Cancer

June 12, 2026

[Oncogene] Researchers showed that cysteine dioxygenase type 1 (CDO1) might be an interesting marker in aggressive forms of prostate cancer. They demonstrated particularly its role in tumor proliferation and its potential regulation by androgen receptor signaling.

Cell-Free DNA in Prostate Cancer and Treatment Selection

June 12, 2026

[Expert Review of Anticancer Therapy] The authors examine the evidence for circulating tumor DNA in prostate cancer management and considers where it may be most effectively integrated into clinical practice.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.